The effects of procaine/haematoporphyrin on age-related decline: a double-blind trial.
A randomized, double-blind study of procaine/haematoporphyrin (KH3) has been carried out over two years in a selected population of healthy elderly subjects. The period of study exceeds 500 patient years. The trial population was weighted to contain a larger proportion of subjects aged over 75 years than a standard population; those receiving active KH3 had similar characteristics on entry to those receiving placebo. Over the course of two years, KH3 was shown to be an active substance in that: (a) decrement in the consolidation of new learning was prevented in the treatment group (less than 1.0%, as against 38% in the placebo group); (b) the prevalence of incontinence increased significantly in the placebo group, but not in the active group (P less than 0.05); (c) there was a significant increase in grip strength in the active treatment group (+22%, P less than 0.01 v. placebo); (d) more adverse reactions were observed on treatment with KH3 (P less than 0.005).
D000368:Aged; D000375:Aging / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006415:Hematoporphyrins / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D007858:Learning / Q000187:drug effects; D008297:Male; D011939:Mental Recall / Q000187:drug effects; D011343:Procaine / Q000009:adverse effects / Q000494:pharmacology*; D011897:Random Allocation; D014549:Urinary Incontinence / Q000517:prevention & control
D004338:Drug Combinations; D006415:Hematoporphyrins; C033990:K.H.3; D011343:Procaine